Le Lézard
Classified in: Business, Covid-19 virus
Subjects: SVY, POL

Avoid Puffery When Applying for COVID-19 Financial Aid, Advises Former Federal Prosecutor


DALLAS, March 30, 2020 /PRNewswire/ -- Owners of companies that plan to apply for financial assistance through the recently enacted Paycheck Protection Program should err on the side of caution, advises white-collar criminal defense attorney and former federal prosecutor Dan Guthrie.

The $349 billion program to help small businesses that have been negatively impacted by the COVID-19 pandemic comes with several parameters. Eligible businesses (those with 500 or fewer employees) can qualify for a loan guaranteed by the U.S. Small Business Administration to cover 2.5 times their monthly payroll average for the period from March 15, 2020 until June 30, 2020. The loan will be totally forgiven, but only if a business can properly document that the money was spent on the following categories: payroll costs, mortgage or rent payments, group health care premiums and retirement benefits.

"This program is really favorable to small businesses, and it will be a lifeline to many who are hurting right now," says Guthrie, of Dallas' Law Offices of Dan C. Guthrie, Jr. "But companies should know that the government is going to be on high alert for fraud. Every U.S. Attorney's office has already been instructed to designate a Coronavirus Fraud Coordinator, so businesses must resist the temptation to inflate the amount of their payroll or do anything else with even a whiff of fraud."

"Those who apply for the funding will be required to attest that all the information they are providing is correct, and 'that any false statements can subject you to civil and criminal liability,'" Guthrie says. "After Hurricane Katrina, the government prosecuted more than 1,400 people for various types of fraud related to that disaster. Because the COVID-19 aid package is so much bigger than Katrina, we will most likely see many times that."

"I understand that most small businesses are really nervous right now," he says. "The future is uncertain. But I would strongly counsel any small company to stay within both the letter and the spirit of the law when seeking this kind of financial assistance."

About the Law Offices of Dan C. Guthrie, Jr.

Dan C. Guthrie, Jr., is an accomplished white-collar criminal defense lawyer with more than 35 years' experience. A former federal and state prosecutor, he is frequently retained during criminal investigations. For more information, visit https://www.whitecollardefense.com/.

CONTACT: Amy Hunt
214-801-8116
[email protected]

SOURCE Law Offices of Dan C. Guthrie, Jr.


These press releases may also interest you

at 08:05
Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody...

at 08:05
Detailed positive results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 08:05
Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to...

1 jun 2024
Long-Term Follow-Up Data Signal Promising Progression-Free Survival (PFS) for Selinexor in the Maintenance Setting with Median PFS of 28.4 Months in the TP53 Wild-Type and 39.5 Months in the Proficient Mismatched Repair Status (pMMR) TP53 Wild-Type...

1 jun 2024
Taseko Mines Limited (LSE: TKO) ("Taseko" or the "Company") announced today that operations at the Company's Gibraltar Mine have been suspended. Collective bargaining with Gibraltar's union representatives has been ongoing in recent weeks, and...

1 jun 2024
Takeda (TSE:4502/NYSE:TAK) and Pfizer today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking...



News published on and distributed by: